Entero Therapeutics ( (ENTO) ) has released a notification of late filing.
Entero Therapeutics, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the ongoing review of the accounting treatment of a significant transaction, which requires additional time to ensure compliance with relevant accounting standards. The company anticipates filing the report within fifteen calendar days following the original due date. Entero Therapeutics does not expect any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Anna Skowron, the Interim Chief Financial Officer, who assured stakeholders of the company’s commitment to maintaining compliance.
More about Entero Therapeutics
YTD Price Performance: -26.15%
Average Trading Volume: 232,616
Technical Sentiment Signal: Buy
Current Market Cap: $2.28M
For a thorough assessment of ENTO stock, go to TipRanks’ Stock Analysis page.